Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

ASH 2024 Summary: Highlights in CML

2024 ASH Annual Meeting Insights Hub

J. Yang

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

Is Post-HSCT Maintenance the SOC for AML?

Rush University Medical Center

M. Levis

Experts Discuss How They Use Asciminib in Their CML Practice

MyCancerHaven

R. Vij, J. Zeidner

Efficacy and Safety of Asciminib in Ph+ CML

Luke Fletcher

ASH 2023 Insights: "Treatment Patterns & Clinical Outcomes Among Pat…

Insights from 2023 ASH Annual Meeting

E. Atallah

Current Treatment Landscape in Myeloid Malignancies

Houston Methodist

S. Shah

Treating Fibrosis and Inflammation in GvHD

Pooja Khandelwal

Updates on Myeloproliferative Neoplasms Including CML

Winship Cancer Institute - Emory University

A. Hunter

Controversies in the Management of CML in 2024

Indy Hematology Review

R. Larson

SOHO 2023: The New ELN Laboratory Recommendations for the Diagnosis …

SOHO 2023 Eleventh Annual Meeting

N. Cross

Highlights of Recent Updates in CML: Impact on Practice

2024 ASCO® Annual Meeting Insights Hub

E. Atallah

Chronic GVHD: Review Advances in Prevention, Novel Endpoints, and Ta…

City of Hope

I. Amanam

How I Treat R/R CML in 2024: Strategies and Emerging Therapies

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Jabbour

TKI Discontinuation in CML: Defining Eligibility Criteria and Predic…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

M. Yassin

Biological Highlights in CML From EHA

International CML Foundation

N. Cross

Understanding and Addressing the Challenges in CML in 2024

Indy Hematology Review

R. Larson